89bio (ETNB) Stock Forecast, Price Target & Predictions
ETNB Stock Forecast
89bio stock forecast is as follows: an average price target of $22.00 (represents a 136.81% upside from ETNB’s last price of $9.29) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ETNB Price Target
The average price target for 89bio (ETNB) is $22.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $12.00. This represents a potential 136.81% upside from ETNB's last price of $9.29.
ETNB Analyst Ratings
According to 8 Wall Street analysts, 89bio's rating consensus is 'Buy'. The analyst rating breakdown for ETNB stock is 1 'Strong Buy' (12.50%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
89bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Brian Abrahams | RBC Capital | $12.00 | $8.03 | 49.44% | 29.17% |
| Jun 07, 2024 | Eliana Merle | UBS | $25.00 | $8.10 | 208.64% | 169.11% |
| May 10, 2024 | Ed Arce | H.C. Wainwright | $29.00 | $9.00 | 222.22% | 212.16% |
The latest 89bio stock forecast, released on Aug 06, 2024 by Brian Abrahams from RBC Capital, set a price target of $12.00, which represents a 49.44% increase from the stock price at the time of the forecast ($8.03), and a 29.17% increase from ETNB last price ($9.29).
89bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $12.00 | $22.00 |
| Last Closing Price | $9.29 | $9.29 | $9.29 |
| Upside/Downside | -100.00% | 29.17% | 136.81% |
In the current month, the average price target of 89bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 89bio's last price of $9.29. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Aug 06, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 07, 2024 | UBS | Buy | Buy | Hold |
| May 14, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 03, 2023 | BTIG | Buy | Buy | Hold |
| Mar 23, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Feb 21, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 11, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Sep 13, 2022 | Raymond James | Strong Buy | Strong Buy | Hold |
89bio's last stock rating was published by Raymond James on Aug 06, 2024. The company gave ETNB a "Strong Buy" rating, the same as its previous rate.
89bio Financial Forecast
89bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $750.00K | $750.00K | - |
| High Forecast | - | - | - | - | $750.00K | $750.00K | - |
| Low Forecast | - | - | - | - | $750.00K | $750.00K | - |
| # Analysts | - | - | - | - | 3 | 7 | - |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ETNB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
89bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 7 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ETNB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 89bio's previous annual EBITDA (undefined) of $NaN.
89bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 7 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-67.89M | $-64.89M | $-66.22M | $-64.89M | $-57.33M | $-62.26M | $-56.35M |
| High Forecast | $-67.89M | $-64.89M | $-66.22M | $-64.89M | $-57.33M | $-58.80M | $-56.35M |
| Low Forecast | $-67.89M | $-64.89M | $-66.22M | $-64.89M | $-57.33M | $-70.33M | $-56.35M |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ETNB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
89bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 7 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ETNB last annual SG&A of $NaN (undefined).
89bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 3 | 7 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.68 | $-0.65 | $-0.66 | $-0.65 | $-0.57 | $-0.62 | $-0.56 |
| High Forecast | $-0.68 | $-0.65 | $-0.66 | $-0.65 | $-0.57 | $-0.59 | $-0.56 |
| Low Forecast | $-0.68 | $-0.65 | $-0.66 | $-0.65 | $-0.57 | $-0.70 | $-0.56 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, 89bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ETNB previous annual EPS of $NaN (undefined).
89bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
| HOOK | HOOKIPA Pharma | $3.76 | $3.00 | -20.21% | Buy |
ETNB Forecast FAQ
Is 89bio a good buy?
Yes, according to 8 Wall Street analysts, 89bio (ETNB) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 6 'Buy' recommendations, accounting for 87.50% of ETNB's total ratings.
What is ETNB's price target?
89bio (ETNB) average price target is $22 with a range of $12 to $29, implying a 136.81% from its last price of $9.29. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will 89bio stock go up soon?
According to Wall Street analysts' prediction for ETNB stock, the company can go up by 136.81% (from the last price of $9.29 to the average price target of $22), up by 212.16% based on the highest stock price target, and up by 29.17% based on the lowest stock price target.
Can 89bio stock reach $14?
ETNB's average twelve months analyst stock price target of $22 supports the claim that 89bio can reach $14 in the near future.
What are 89bio's analysts' financial forecasts?
89bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.5M (high $1.5M, low $1.5M), average EBITDA is $0 (high $0, low $0), average net income is $-176M (high $-172M, low $-184M), average SG&A $0 (high $0, low $0), and average EPS is $-1.762 (high $-1.728, low $-1.843). ETNB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-264M (high $-264M, low $-264M), average SG&A $0 (high $0, low $0), and average EPS is $-2.643 (high $-2.643, low $-2.643).